Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF1a) for the treatment of infections, which may be caused by bacteria, viruses, yeasts, fungi, or parasites. Further disclosed are phannaceutical compositions comprising HIF-1a prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1a. Compounds used in the disclosed compositions and methods include: 1-Benzyl-3-hydroxy-4-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]pyridin-2(1H)-one； 1-Benzyl-3-hydroxy-4-(thiazolidin-3-ylmethyl)pyridin-2(1H)-one； 1-Benzyl-3-hydroxy-4-(piperidin-1-ylmethyl)pyridin-2(1H)-one and 1-(4&rsquo；-Methylbenzenesulfonyl)-3-hydroxy-4-[(2-methoxyethylamino)methyl]-pyridin-2(1H)-one.
